
    
      OBJECTIVES:

        -  Determine the safety and efficacy of thalidomide in patients with metastatic low-grade
           neuroendocrine tumors.

      OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8. Courses repeat every 8
      weeks in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
    
  